Introduction:
The global biosimilars market is rapidly expanding, with an increasing number of countries and companies participating in tender processes to secure a share of this lucrative industry. In 2021, the global biosimilars market was valued at $14.5 billion, with a projected growth rate of 25% by 2026. This report will explore the top 20 leading biosimilars tender processes worldwide in 2026.
1. United States:
– Market size: $3.2 billion
– The United States remains a key player in the biosimilars market, with a robust tender process that attracts leading pharmaceutical companies aiming to secure a share of the market.
2. Germany:
– Market share: 25%
– Germany is a frontrunner in biosimilars tender processes, with a well-established regulatory framework that supports the development and approval of biosimilars.
3. South Korea:
– Production volume: 150,000 units
– South Korea has emerged as a significant player in the biosimilars market, with a growing number of companies participating in tender processes to expand their market presence.
4. India:
– Exports: $500 million
– India is a major exporter of biosimilars, with a competitive tender process that attracts international pharmaceutical companies looking to partner with Indian manufacturers.
5. Japan:
– Market size: $1.5 billion
– Japan has a strong biosimilars market, with a transparent tender process that encourages competition and innovation in the industry.
6. Pfizer:
– Market share: 10%
– Pfizer is a leading pharmaceutical company in the biosimilars market, with a successful track record in securing tender contracts worldwide.
7. Novartis:
– Exports: $300 million
– Novartis is a key player in biosimilars tender processes, with a diverse portfolio of products that cater to different therapeutic areas.
8. Teva Pharmaceuticals:
– Market share: 8%
– Teva Pharmaceuticals is a prominent player in the biosimilars market, with a strong focus on research and development to expand its product offerings.
9. Samsung Bioepis:
– Production volume: 100,000 units
– Samsung Bioepis is a leading biosimilars manufacturer, with a state-of-the-art production facility and a strategic approach to tender processes.
10. Sandoz:
– Market size: $800 million
– Sandoz, a subsidiary of Novartis, is a key player in biosimilars tender processes, with a global presence and a commitment to quality and affordability.
11. Brazil:
– Market share: 12%
– Brazil has a growing biosimilars market, with a competitive tender process that encourages local and international companies to participate.
12. China:
– Exports: $700 million
– China is a major player in the biosimilars market, with a focus on expanding its presence in international tender processes to strengthen its position in the industry.
13. Biogen:
– Market size: $600 million
– Biogen is a leading biotechnology company with a strong presence in biosimilars tender processes, leveraging its expertise in research and development.
14. Amgen:
– Market share: 6%
– Amgen is a key player in the biosimilars market, with a focus on developing high-quality products that meet the needs of patients and healthcare providers.
15. France:
– Production volume: 120,000 units
– France has a growing biosimilars market, with a well-defined tender process that attracts leading pharmaceutical companies to invest in the country.
16. Roche:
– Exports: $400 million
– Roche is a major player in biosimilars tender processes, with a strong global presence and a commitment to innovation and quality.
17. AbbVie:
– Market size: $700 million
– AbbVie is a leading pharmaceutical company with a significant presence in biosimilars tender processes, focusing on developing affordable and accessible treatments.
18. Australia:
– Market share: 8%
– Australia has a competitive biosimilars market, with a transparent tender process that promotes competition and innovation in the industry.
19. Merck:
– Production volume: 80,000 units
– Merck is a key player in biosimilars tender processes, with a diverse portfolio of products that cater to different therapeutic areas.
20. Spain:
– Exports: $200 million
– Spain has a growing biosimilars market, with a focus on expanding its presence in international tender processes to attract leading pharmaceutical companies to invest in the country.
Insights:
The biosimilars market is expected to continue its rapid growth, with an increasing number of countries and companies participating in tender processes to secure a share of this expanding industry. By 2026, the global biosimilars market is projected to reach $30 billion, driven by factors such as increasing demand for affordable biologics and growing investments in research and development. Countries with well-established regulatory frameworks and transparent tender processes are likely to attract more investments and partnerships from leading pharmaceutical companies, further driving the growth of the biosimilars market worldwide.
Related Analysis: View Previous Industry Report
